Moteur de recherche d’entreprises européennes
Financement de l’UE (3 983 592 €) : Organoïdes pour la recherche sur les virus - Un programme de formation innovant ETN Hor12/11/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Organoïdes pour la recherche sur les virus - Un programme de formation innovant ETN
OrganoVIR (Organoids for Virus Research) will train young researchers (ESRs) in the field of organoids and virology. Human viral infection studies lack suitable experimental models as animal models or conventional 2-dimensional (2D) cell cultures do not translate to human infection. OrganoVIR makes use of the breakthrough in the culturing of primary human cells into 3D cultures (organoids). Within this ETN programme, organoids will be used for the first time to study human viral infections in their natural environment. OrganoVIR includes leading partners in virology and organoid technology covering 7 academic institutes, 3 life science companies, 1 organoid technology private company, 2 non-profit organisations, a national public health institute and a business school originating from 8 countries. The aim is to introduce and establish human organoids as superior models for viral pathogenesis studies and antiviral testing, thus replacing animal models and reducing animal use. OrganoVIR provides a full package ETN programme for ESRs to learn the science of innovative 3D culture systems for virus research as well as financial, commercial, ethical, communicative, policy and dissemination aspects for optimal valorization. The projects are intensified by significant secondments at commercial, governmental and non-profit partner institutes. OrganoVIR provides: - High-ranked scientific and technical training in an interdisciplinary, intersectoral and international top research project - Training in transferrable managerial skills, including a pre-MBA - Implementation of innovative organoid technology for viral pathogenesis studies and antiviral development - Innovation in organoid technology by co-culture design and high throughput screening. OrganoVIR combines frontier research with an innovative training programme in a complementary network, certifying high impact scientists.
| Epithelix Sàrl | ? |
| Academisch Medisch Centrum BIJ DE Universiteit Van Amsterdam | 531 240 € |
| Charles River Nederland B.V. | 265 620 € |
| Danmarks Tekniske Universitet | 297 522 € |
| Katholieke Universiteit Leuven | 768 960 € |
| Stemcell Technologies UK Ltd. | 303 173 € |
| Universite Clermont Auvergne | 549 604 € |
| Universite DE Geneve | 281 277 € |
| Universiteit Utrecht | 265 620 € |
| Universiteit Van Amsterdam | 265 620 € |
| Uniwersytet Jagiellonski | 454 957 € |
https://cordis.europa.eu/project/id/812673
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Epithelix Sàrl, Plan-les-Ouates, Suisse.